May 3, 2018
From a bedroom start-up to life saving technology
Award-wining medical technology start-up MediSieve has announced its move to prestigious new offices, capping a period of rapid growth, as well as adding a new team member.
Award-wining medical technology start-up MediSieve has announced its move to prestigious new offices, capping a period of rapid growth, as well as adding a new team member. The company, best known for their revolutionary new technology that fights disease using magnetic blood filtration, will be working at The Translation & Innovation Hub (I-HUB), part of the Imperial College London Incubator for science companies. The workspace in London's White City is designed as an innovation and collaboration hub for growing technology startups, and established biotech businesses.
MediSieve has also appointed Dr Alice Mazzer to the four-person team as a Product Development Chemist/Biochemist. Specialising in chromatography and structural biology, Alice will be focussing on the development of magnetic particles to broaden the potential medical applications of MediSieve’s magnetic blood filtration technology. Dr George Frodsham, founder and CEO of MediSieve, said "I'm very happy to welcome Alice to the company. Alice’s experience will be paramount in helping the team to develop products that have applications in diseases beyond Malaria, including Sepsis and Leukaemia.”
Alice's previous roles include Postdoctoral Research Associate at University College London where amongst other responsibilities, she developed analytical methods to identify design flaws in new purification technology for biologics. The new role will see Alice work with the team to develop new techniques to functionalise magnetic beads with antibodies, aptamers and other entities.
Dr Frodsham continues, "We are a start-up in the true sense of the term. I started the business in my bedroom. We were previously renting and borrowing space and having access to equipment was always an issue. Having the labs has hugely increased our R&D capability, meaning that we are quicker and much more cost-effective.” The expansion of the business into a new, purpose-built R&D facility comes on the back of a string of successes for MediSieve, including a £150,000 grant by the National Institute of Health Research to start first clinical studies of their magnetic blood filtration device. While MediSieve's new laboratories are in the Imperial Incubator, their offices are in Central Working, located within the same building. Central Working provides modern, spacious and well-equipped facilities that enable start-ups and established businesses to work together.
About Magnetic Blood Filtration
MediSieve's Magnetic Blood Filtration Platform is intended to enable the rapid and specific depletion of specific agents from the bloodstream of patients. The extracorporeal therapy uses therapeutic Magnetic Beads that are designed to bind specifically to the clinical target. The Beads are introduced into the extracorporeal circuit during the therapy, mixing with the patient’s blood and binding to the clinical targets. The Delivery Platform captures all the Magnetic Beads and bound targets, preventing their return to the patient.
MediSieve is a London-based BioTech start-up that has developed Magnetic Blood Filtration, a revolutionary platform therapy that enables the physical removal of specific substances from the bloodstream of patients. It can be used (1) as a direct treatment, (2) to increase the safety and efficacy of other therapies, or (3) to enable personalised medicine. The company is a spin-off from University College London and is developing its products at the White City Innovation District in West London. MediSieve is actively seeking investment and partnerships.
INVESTOR AND PARTNERSHIP CONTACT: